BRAIN and NERVE－神経研究の進歩68巻7号

2016年07月発行

増大特集 認知症の危険因子と防御因子

認知症における加齢と性差

著者： 亀山祐美¹ 秋下雅弘¹

所属機関： ¹東京大学医学部附属病院老年病科

ページ範囲：P.713 - P.718

文献概要

認知症の危険因子として加齢，女性，生活習慣病などが挙げられる。また孤発性アルツハイマー病ではアポリポ蛋白Eε4アリルが遺伝的危険因子といわれているが，年齢や性による違いも報告されている。加齢に伴いアンドロゲン，女性ホルモン，男性ホルモンは低下し，認知機能低下や認知症発症とも関連することがわかってきた。予防としてのホルモン補充療法は大変興味深く，今後検討してゆくべき命題だと思われる。

参考文献

1)Dodge HH, Buracchio TJ, Fisher GG, Kiyohara Y, Meguro K, et al: Trends in the prevalence of dementia in Japan. Int J Alzheimers Dis 2012: 956354, 2012

2)厚生労働科学研究費補助金認知症対策総合研究事業: 都市部における認知症有病率と認知症の生活機能障害への対応. 平成23年度〜24年度総合研究報告書. 2013

3)Sekita A, Ninomiya T, Tanizaki Y, Doi Y, Hata J, et al: Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community: the Hisayama Study. Acta Psychiatr Scand 122: 319-325, 2010

4)Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, et al: Incidence of Dementia over Theree Decades in the Framingham Heart Study. N Engl J Med 374: 523-532, 2016

5)Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, et al: Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis 21: 691-724, 2010

6)Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, et al: Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 77: 1126-1134, 2011

7)Mukai N, Doi Y, Ninomiya T, Hirakawa Y, Nagata M, et al: Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: The Hisayama Study. J Diabetes Investig 5: 162-169, 2014

8)Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, et al: Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension 58: 22-28, 2011

9)Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, et al: Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42: 776-782, 1997

10)亀山美, 山口　潔, 木棚　究, 石井伸弥, 小島太郎, 他: アルツハイマー病患者と介護者の食習慣の傾向とその性差（会議録）. 日本老年医学会雑誌51（臨増）: 102, 2014

11)Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, et al: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287: 3230-3237, 2002

12)Sabia S, Elbaz A, Britton A, Bell S, Dugravot A, et al: Alcohol consumption and cognitive decline in early old age. Neurology 82: 332-339, 2014

13)Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, et al: Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 62: 953-957, 2005

14)Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, et al: Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 152: 475-488, 2000

15)Riedel BC, Thompson PM, Brinton RD: Age, APOE and sex: triad of risk of Alzheimer's disease. J Steroid Biochem Mol Biol 160: 134-147, 2016

16)Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8: 1-21, 1988

17)Seet WT, Mary Anne TJ, Yen TS: Apolipoprotein E genotyping in the Malay, Chinese and Indian ethnic groups in Malaysia: a study on the distribution of the different apoE alleles and genotypes. Clin Chim Acta 340: 201-205, 2004

18)Jorm AF, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, et al: Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20 (Suppl 2): S43-S47, 1991

19)Barrett-Connor E, Goodman-Gruen D, Patay BJ: Endogenous sex hormones and cognitive function in older men. Clin Endocrinol Metab 84: 3681-3685, 1999

20)Chu LW, Tam S, Wong RL, Yik PY, Song Y, et al: Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. J Alzheimers Dis 21: 1335-1345, 2010

21)Lacroix C, Fiet J, Benais JP, Gueux B, Bonete R, et al: Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain. J Steroid Biochem 28: 317-325, 1987

22)Sunderland T, Merril CR, Harrington MG, Lawlor BA, Molchan SE, et al: Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet 2: 570, 1989

23)Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, et al: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86: 724-731, 2001

24)Ota H, Akishita M, Akiyoshi T, Kahyo T, Setou M, et al: Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice: protective role of eNOS and SIRT1. PLOS ONE 7: e29598, 2012

25)Ooishi Y, Kawato S, Hojo Y, Hatanaka Y, Higo S, et al: Modulation of synaptic plasticity in the hippocampus by hippocampus-derived estrogen and androgen. J Steroid Biochem Mol Biol 131: 37-51, 2012

26)Cummings JL, Vinters HV, Cole GM, Khachaturian ZS: Alzheimer's disease: etiologies, pathology, cognitive reserve, and treatment opportunities. Neurology 51 (1 Suppl 1): S2-S17; discussion S65-S67, 1998

27)Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, et al: Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 54: 833-837, 2000

28)Fukai S, Akishita M, Yamada S, Toba K, Ouchi Y: Effects of testosterone in older men with mild-to-moderate cognitive impairment. J Am Geriatr Soc 58: 1419-1421, 2010

29)Yamada S, Akishita M, Fukai S, Ogawa S, Yamaguchi K, et al: Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. Geriatr Gerontol Int 10: 280-287, 2010

30)Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651-2662, 2003

31)LeBlanc ES, Janowsky J, Chan BK, Nelson HD: Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285: 1489-1499, 2001

32)Marjoribanks J, Farquhar C, Roberts H, Lethaby A: Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 7: CD004143, 2012

33)O'Brien J, Jackson JW, Grodstein F, Blacker D, Weuve J: Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease. Epidemiol Rev 36: 83-103, 2014

34)Hong Y, Wang X, Sun S, Xue G, Li J, et al: Progesterone exerts neuroprotective effects against Aβ-induced neuroinflammation by attenuating ER stress in astrocytes. Int Immunopharmacol 33: 83-89, 2016